{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277569","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.239686+00:00","generated_at":"2026-05-16T21:49:29.954407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kyverna Therapeutics reports Q3 results, positive gMG interim data, $150M loan facility, SPS data early 2026","bullets":["Kyverna reported Q3 2025 net loss of $36.8M ($0.85 per share), R&D expenses $30.5M, G&A $8.3M; cash $171.1M as of Sep 30, 2025.","Positive interim Phase 2 data in generalized myasthenia gravis: all primary and secondary endpoints met, 100% of patients achieved sustained reductions in MG-ADL and QMG at 24 weeks.","Topline data from registrational stiff person syndrome trial expected early 2026 (narrowed from 1H 2026); BLA submission anticipated in 1H 2026.","Closed up to $150M loan facility with Oxford Finance, initial $25M drawn; cash runway extended into 2027.","On track to file IND for KYV-102 (whole blood rapid manufacturing) in Q4 2025; Phase 3 gMG enrollment by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277569","json":"https://secwatch.observer/filing/0001193125-25-277569.json","markdown":"https://secwatch.observer/filing/0001193125-25-277569.md","text":"https://secwatch.observer/filing/0001193125-25-277569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525277569/0001193125-25-277569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525277569/kytx-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T21:49:29.954407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}